IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸外科
学科主题临床医学
A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma
Lv, Chao1; Ma, Yuanyuan1; Feng, Qin2; Fang, Fang1; Bai, Hua3; Zhao, Bingtian1; Yan, Shi1; Wu, Nan1; Zheng, Qingfeng1; Li, Shaolei1; Chen, Jinfeng1; Wang, Jia1; Feng, Yuan1; Wang, Yuzhao1; Pei, Yuquan1; Fang, Jian4; Yang, Yue1
关键词Non-small-cell Lung Cancer Sequential Induction Chemotherapy Egfr Mutation Adenocarcinoma
刊名WORLD JOURNAL OF SURGICAL ONCOLOGY
2013-04-26
DOI10.1186/1477-7819-11-96
11
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Surgery
资助者Zhejiang Beta Pharma Inc. ; Zhejiang Beta Pharma Inc.
研究领域[WOS]Oncology ; Surgery
关键词[WOS]TYROSINE KINASE INHIBITOR ; FACTOR RECEPTOR MUTATIONS ; PHASE-III ; EGFR MUTATIONS ; CANCER ; GEFITINIB ; CISPLATIN ; TRIAL ; CARBOPLATIN ; COMBINATION
英文摘要

Background: A phase II clinical trial previously evaluated the sequential administration of erlotinib after chemotherapy for advanced non-small-cell lung cancer (NSCLC). This current pilot study assessed the feasibility of sequential induction therapy in patients with stage IIB to IIIA NSCLC adenocarcinoma.

Methods: Patients received gemcitabine 1,250 mg/m(2) on days 1 and 8 and cisplatin 75 mg/m(2) on day 1, followed by oral icotinib (125 mg, three times a day) on days 15 to 28. A repeatcomputed tomography(CT) scan evaluated the response to the induction treatment after two 4-week cycles and eligible patients underwent surgical resection. The primary objective was to assess the objective response rate (ORR), while EGFR and KRAS mutations and mRNA and protein expression levels of ERCC1 and RRM1 were analyzed in tumor tissues and blood samples.

Results: Eleven patients, most with stage IIIA disease, completed preoperative treatment. Five patients achieved partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria (ORR=45%) and six patients underwent resection. Common toxicities included neutropenia, alanine transaminase (ALT) elevation, fatigue, dry skin, rash, nausea, alopecia and anorexia. No serious complications were recorded perioperatively. Three patients had exon 19 deletions and those with EGFR mutations were more likely to achieve a clinical response (P=0.083). Furthermore, most cases who achieved a clinical response had low levels of ERCC1 expression and high levels of RRM1.

Conclusions: Two cycles of sequentially administered gemcitabine/cisplatin with icotinib as an induction treatment is a feasible and efficacious approach for stage IIB to IIIA NSCLC adenocarcinoma, which provides evidence for the further investigation of these chemotherapeutic and molecularly targeted therapies.

语种英语
资助者Zhejiang Beta Pharma Inc. ; Zhejiang Beta Pharma Inc.
WOS记录号WOS:000318495600001
Citation statistics
Cited Times:17[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50185
Collection北京大学临床肿瘤学院_胸外科
作者单位1.Peking Univ, Canc Hosp & Inst, Dept Pathol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
2.Peking Univ, Canc Hosp & Inst, Dept Thorac Surg 2, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
3.Peking Univ, Canc Hosp & Inst, Dept Thorac Med Oncol 1, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
4.Peking Univ, Canc Hosp & Inst, Dept Thorac Med Oncol 2, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
Recommended Citation
GB/T 7714
Lv, Chao,Ma, Yuanyuan,Feng, Qin,et al. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma[J]. WORLD JOURNAL OF SURGICAL ONCOLOGY,2013,11.
APA Lv, Chao.,Ma, Yuanyuan.,Feng, Qin.,Fang, Fang.,Bai, Hua.,...&Yang, Yue.(2013).A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.WORLD JOURNAL OF SURGICAL ONCOLOGY,11.
MLA Lv, Chao,et al."A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma".WORLD JOURNAL OF SURGICAL ONCOLOGY 11(2013).
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Lv, Chao]'s Articles
[Ma, Yuanyuan]'s Articles
[Feng, Qin]'s Articles
百度学术
百度学术Similar articles in
[Lv, Chao]'s Articles
[Ma, Yuanyuan]'s Articles
[Feng, Qin]'s Articles
必应学术
必应学术Similar articles in
[Lv, Chao]'s Articles
[Ma, Yuanyuan]'s Articles
[Feng, Qin]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.